Cephalexin and Comminuted fracture - a phase IV clinical study of FDA data

Summary:

Comminuted fracture is reported as a side effect among people who take Cephalexin (cephalexin), especially for people who are female, 60+ old, also take Prilosec, and have Bone lesion.

The phase IV clinical study analyzes which people have Comminuted fracture when taking Cephalexin. It is created by eHealthMe based on reports of 29,149 people who have side effects when taking Cephalexin from the FDA, and is updated regularly.

What is Cephalexin?

Cephalexin has active ingredients of cephalexin. It is often used in infection. eHealthMe is studying from 30,581 Cephalexin users. Check the latest studies of Cephalexin.

What is Comminuted fracture?

Comminuted fracture (bone has broken into several pieces) is found to be associated with 175 drugs and 135 conditions by eHealthMe. Check the latest studies of Comminuted fracture.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

29,149 people reported to have side effects when taking Cephalexin.
Among them, 12 people (0.04%) have Comminuted fracture.

$Could Cephalexin cause Comminuted fracture?$

Among these 12 people:

What is the gender of people who have Comminuted fracture when taking Cephalexin? *

female: 100 %
male: 0.0 %

What is the age of people who have Comminuted fracture when taking Cephalexin? *

What are other drugs people take besides Cephalexin? *

What are other side effects people have besides Comminuted fracture? *

Fall: 10 people, 83.33%
Pain In Extremity: 10 people, 83.33%
Joint Pain: 9 people, 75.00%
Hip Fracture: 8 people, 66.67%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 8 people, 66.67%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 8 people, 66.67%
Stress And Anxiety: 8 people, 66.67%
High Blood Pressure: 7 people, 58.33%
Emotional Distress: 7 people, 58.33%
Exostosis (formation of new bone on the surface of a bone): 7 people, 58.33%

What are the existing conditions these people have? *

Upper Respiratory Tract Infection: 7 people, 58.33%
Restless Leg Syndrome (a powerful urge to move your legs): 7 people, 58.33%
Pain: 7 people, 58.33%
Muscle Spasms (muscle contraction): 7 people, 58.33%
Multiple Myeloma (cancer of the plasma cells): 7 people, 58.33%
Bone Lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries): 7 people, 58.33%
Osteoporosis (bones weak and more likely to break): 4 people, 33.33%
Type 2 Diabetes: 1 person, 8.33%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Cephalexin and have Comminuted fracture?

- Check whether Comminuted fracture is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cephalexin:

Cephalexin (30,581 reports)

Browse all side effects of Cephalexin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Comminuted fracture:

Comminuted fracture (175 drugs)

Browse all the conditions that are associated with Comminuted fracture:

Comminuted fracture (135 conditions)

Related publications that referenced our studies

Agrawal A, Rao M, Jasdanwala S, Mathur A, Eng M, "Cephalexin Induced Cholestatic Jaundice", Case reports in gastrointestinal medicine, 2014 Aug .
Agrawal A, Rao M, Jasdanwala S, Mathur A, Eng M, "Cephalexin Induced Cholestatic Jaundice", Case reports in gastrointestinal medicine, 2014 Aug .

How the study uses the data?

The study uses data from the FDA. It is based on cephalexin (the active ingredients of Cephalexin) and Cephalexin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.